Vistagen Therapeutics Inc Dossier - Source-backed chat

Vistagen Therapeutics Inc

VTGNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.63

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.31Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $13.7M

Enterprise Value −$3.3M

Shares Outstanding 49.1M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vistagen Therapeutics is a late clinical-stage biopharmaceutical company pioneering nose-to-brain neurocircuitry-focused intranasal pherines. The company's near-term investment thesis is highly binary, centered entirely on the upcoming Phase 3 PALISADE-4 trial readout for fasedienol in social anxiety disorder (SAD) expected in June 2026. Following the failure of the PALISADE-3 trial in December 2025, Vistagen refined its statistical analysis plan for PALISADE-4 to incorporate baseline pre-dose SUDS scores as a covariate, aligning with FDA guidance. While the company has achieved the minimum ICH E1 safety exposure recommendations with over 1,500 subjects exposed, regulatory and clinical risks remain high. With $45.4 million in cash as of March 31, 2026, providing a runway into 2027, a 'Hold' rating is recommended pending the critical PALISADE-4 data release.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$1.00

High · most bullish analyst$1.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3015%

PALISADE-4 fails to meet its primary endpoint, mirroring the PALISADE-3 failure. This outcome would severely damage the clinical viability of fasedienol for SAD, forcing Vistagen to pivot to earlier-stage pipeline assets like refisolone or itruvone. The company would face immediate capital constraints, necessitating highly dilutive financing or strategic restructuring.

Base CaseCentral scenario

$1.0045%

Matches the consensus mean

The PALISADE-4 trial yields mixed or marginally positive results, requiring further discussions with the FDA regarding the regulatory pathway and potential additional clinical trials. The company continues to advance its Phase 2 repeat-dose study and prepares for refisolone's Phase 2 trial in menopausal hot flashes, while managing its cash runway into 2027 through disciplined capital allocation.

Bull CaseUpside scenario

$1.5040%

The PALISADE-4 trial achieves its primary endpoint with statistical significance, successfully replicating the positive results of PALISADE-2. The refined statistical analysis plan successfully mitigates placebo response variability. This positive readout, combined with established safety exposure data, provides a clear path for a U.S. NDA submission in late 2026 or early 2027, positioning fasedienol as the first fast-acting, as-needed treatment for social anxiety disorder.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Novel nose-to-brain pherine platform offers rapid-onset, non-systemic, and non-addictive therapeutic potential without the safety liabilities of benzodiazepines.
Achieved minimum ICH E1 safety exposure recommendations with over 1,500 subjects exposed, establishing a robust safety database for fasedienol.
Refined statistical analysis plan for PALISADE-4 incorporates baseline SUDS scores as a covariate, which has been acknowledged by the FDA without further comments.

Key Investment Risks

High binary clinical trial risk, with fasedienol's regulatory pathway heavily dependent on the imminent PALISADE-4 readout.
History of clinical setbacks, including the failure of the PALISADE-3 Phase 3 trial to meet its primary endpoint in December 2025.
Limited cash runway extending only into 2027, which will require additional capital raises or strategic partnerships to fund commercialization or further pipeline development.

Thesis Invalidation Triggers

Failure of the PALISADE-4 Phase 3 trial to achieve statistical significance on its primary efficacy endpoint.
FDA refusal to accept a potential NDA submission based on the combined PALISADE-2 and PALISADE-4 datasets.
Inability to secure additional financing or strategic partnerships, leading to a severe liquidity crisis before 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.